Patent Baristas

The Antitrust Review blog reported that the Solicitor General’s Office submitted a brief to the Supreme Court urging the Court to deny certiorari in the reverse payment case Joblove v. Barr Labs (S.Ct. No. 06-830). Earlier, the Supreme Court had asked for the government’s views on the antitrust effects of settlement agreements between holders of […]

Hal Wegner at Foley & Lardner circulated a note about a letter by Chief Justice Paul Michel of the United States Court of Appeals for the Federal Circuit. Hal writes: One of the two most divisive points ripping apart patent reform legislation is the ever more contentious debate over apportionment of damages, as witnessed by […]

What Is It? Camargo Pharmaceutical Services is offering a one-day training workshop to help those without drug expertise understand the basic aspects of drug discovery; drug effects, clinical development and testing of drugs; bioanalytical chemistry, and drug absorption, distribution, metabolism, and excretion in the body. Who Should Attend? This course is designed for people working […]

The U.S. Court of Appeals for the Federal Circuit smacked down Pfizer’s bid to get the court to reconsider a March 22 ruling that the patent on its hypertension drug Norvasc was invalid. See Pfizer v. Apotex (06-1261). The earlier ruling allowed Mylan Labs to make a generic version of Norvasc. Mylan entered the market […]

EFF Wants You to Help Stop Broadcasting Treaty Flip-Flop The Electronic Frontier Foundation (EFF) wants to mobilize businesses, public interest groups, and creative industry representatives to stand up against what it sees as over-broad protection of broadcast material. The World Intellectual Property Organization (WIPO) has been debating a treaty that could severly inhibit digital devices […]

The General Counsel for the Department of Commerce (DOC), as overlord of the U.S. Patent and Trademark Office (USPTO), sent its own views on the provisions of H.R. 1908, the “Patent Reform Act of 2007,” to Howard L. Herman Chairman of the Subcommittee on Courts, the Internet, and Intellectual Property, Committee on the Judiciary. This […]

A letter went out today to Speaker of the House Nancy Pelosi, Senate Majority Leader Harry Reid, House Minority Leader John Boehner, Senate Minority Leader, and Mitch McConnell from 111 companies across 27 states expressing concern over certain provisions of patent reform legislation (H.R. 1908/S. 1145 – The Patent Reform Act of 2007) currently under […]

The U.S. Supreme Court rebuffed an appeal from Amgen, which tried to have the Supreme Court review the Federal Circuit’s practice of drawing its own conclusions about patent claims rather than relying solely on findings made by the trial court. See Amgen Inc. v. Hoechst Marion Roussel Inc. and Transkaryotic Therapies Inc., 06-1291. Earlier, the […]